文献速递慢性肾脏病血液净化与透析肾移植

评估Medicare Advantage星级措施:对肾脏照护质量的影响与未来机遇

Assessment of Medicare Advantage Stars Measures: Impact on Kidney Care Quality and Future Opportunities.
PubMed 文献 · J Am Soc Nephrol · 2026-07-09

美国肾脏病学会质量委员会工作组采用改良ACP标准评估2026年Medicare Part C和D星级措施中25项临床相关指标。仅1项涉及指南导向肾脏照护(糖尿病患者的白蛋白尿筛查),无CKD筛查、肾脏病转诊、肾脏药物治疗等指标。结论认为星级措施错失了改善肾脏病患者结局的机会。

要点

  • 2026年星级措施中仅1项覆盖指南导向肾脏照护(糖尿病白蛋白尿筛查)。
  • 缺乏CKD筛查、风险分层、肾脏病转诊、肾脏药物治疗等指标。

核心结论

  • 2026年Medicare Part C和D星级措施错失了将照护措施与指南导向肾脏照护对齐的机会,未能改善肾脏病患者的结局、降低费用和推进高价值照护。

研究设计与样本

  • 美国肾脏病学会质量委员会召集工作组,采用改良美国内科医师学会措施评审标准,评估2026年Medicare Part C和D星级质量措施中25项直接与临床结局相关的指标(共45项)。

主要发现

  • 工作组识别出13项高有效性星级措施,监测糖尿病、高血压和照护过渡相关照护。
  • 识别出12项中等有效性措施,评估预防性照护和其他慢性照护领域。
  • 星级措施在肾衰竭患者中的适当性和临床证据基础通常较强但较弱。
  • 仅1项措施涵盖指南导向肾脏照护,即糖尿病患者的白蛋白尿筛查。

关键数值与推荐

  • 2021年ESRD在Medicare Advantage中的入组比例<30%,2024年超过50%。
  • 评估了45项星级质量措施中的25项直接与临床结局相关的措施。

临床怎么用

  • 肾内科医生应了解当前星级措施对肾脏照护覆盖不足,在临床实践中主动补充CKD筛查、风险分层、肾脏病转诊和肾脏药物治疗等指南推荐照护。

局限性

  • 评估仅纳入25项直接与临床结局相关的星级措施,排除了非临床结局措施(如客户服务)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Centers for Medicare & Medicaid Services uses the Star quality program to evaluate Medicare Advantage (Medicare Part C) care quality. Since the 21st Century Cures Act, ESRD enrollment within Medicare has shifted from <30% in 2021 with Medicare Advantage to more than 50% in 2024. Given this influx and growing CKD prevalence, evaluating how Stars measures shape kidney care has significant population health implications. The American Society of Nephrology Quality Committee convened a working group to assess the 2026 Medicare Part C and D Stars quality measures. Measures were reviewed using a modified American College of Physicians Measure Review Criteria, which evaluates measure importance, appropriateness, evidence base, specifications, and feasibility, and Stars measures evaluating nonclinical outcomes were excluded ( e.g ., customer service). The American Society of Nephrology committee evaluated 25 (of 45) Star quality measures that were directly related to clinical outcomes. The committee assessment identified 13 high-validity Star measures that monitored care related to diabetes, hypertension, and care transitions, as well as 12 medium-validity measures that evaluated preventive care and other chronic care areas. The appropriateness and clinical evidence base of Star measures were generally strong but weaker in patients with kidney failure. The committee noted concerns with ten Stars measures that may exclude patients with kidney failure. Only one measure captured guideline-directed kidney care (albuminuria screening in patients with diabetes). No Stars measures captured other guideline-directed recommendations, such as CKD screening and risk stratification, nephrology referral, use of kidney pharmacotherapies, CKD education, or preemptive kidney transplantation referral. The Medicare 2026 Part C and D Stars measures represent a missed opportunity to align care measures and guideline-directed kidney care to improve outcomes, reduce costs, and advance high-value care for the millions of Americans living with kidney disease.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Le D, Ahearn L, Wilk AS, et al. Assessment of Medicare Advantage Stars Measures: Impact on Kidney Care Quality and Future Opportunities. J Am Soc Nephrol. 2026. PMID: 42424117. doi:10.1681/ASN.0000001200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。